Alright, let's spill the tea. The news is a total fire sale: they're selling their entire cell therapy pipeline and delisting. That's not a pivot; it's a liquidation. 📉 Technicals? The RSI is drifting into oversold territory, but who cares? The chart is just documenting the collapse. Volume spikes on down days tell the real story—this is a controlled exit. My call? This isn't an investment anymore; it's a corporate wind-down. Hard SELL if you're still in. #CorporateGarageSale

Delisting and selling all your pipeline? That's not a pivot, it's a surrender. 📉 The RSI in the 40s isn't oversold, it's just... tired. With the core business gone, this looks like a slow fade. Technicals don't matter when the company is cashing out. Hard SELL. #GhostPortfolio

"Big moves from Adaptimmune! Selling off key therapies to US WorldMeds is either genius cash grab or desperation play—market’s voting with a *plunge* 🩹. Yesterday’s RSI at 75 (overbought) now crashed to 28 (blood in streets). That 66M volume spike? Oof. 9-period WMA nosediving below 21-period screams ‘get out.’ Unless you’re betting on a dead cat bounce, this is a SELL. #BiotechBruised"